NEXGEL Reschedules 2025 Financial Results Conference Call to April 8th at 4:30 P.M. ET to Provide Shareholders with an Update on Its Previously Announced Transaction with Celularity
Rhea-AI Summary
NEXGEL (NASDAQ:NXGL) rescheduled its fourth quarter and full-year 2025 financial results conference call to April 8, 2026 at 4:30 P.M. ET to allow more time to provide shareholders detail on its previously announced proposed transaction with Celularity.
The company filed its Form 10-K for year ended December 31, 2025 with the SEC on March 31, 2026. Call dial-in numbers and a webcast will be available for investors.
Positive
- None.
Negative
- None.
News Market Reaction – NXGLW
In the Apr 1 session, NXGLW declined 18.36%, reflecting a significant negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Conferences,earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 03 | Earnings call scheduling | Neutral | -10.4% | Announcement of Q3 2025 results date and investor conference call logistics. |
| Aug 06 | Earnings call scheduling | Neutral | +4.5% | Notice of Q2 2025 results release and related conference call details. |
| May 09 | Earnings call scheduling | Neutral | -7.5% | Scheduling first quarter 2025 financial results and investor call timing. |
| Mar 19 | Earnings call scheduling | Neutral | +3.1% | Setting date for Q4 and full-year 2024 results and conference call. |
| Nov 11 | Earnings call scheduling | Neutral | -7.9% | Announcement of Q3 2024 results date and related conference call plans. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Scheduling earnings and conference calls for NXGL has historically produced mixed reactions, with a slight tendency toward negative moves and several notable downside responses.
Recent NXGL news centered on acquisitions and strategic restructuring. In Dec 2024–Dec 2025, the company spun off its drug delivery assets into NexGelRx, retaining a 19.99% stake and royalty interests, and later secured additional NexGelRx investment and a new strategic advisor. In early 2026, NXGL pursued a Celularity portfolio acquisition with multiple financing steps. Against this backdrop, today’s rescheduled 2025 results call continues the pattern of using earnings events to update investors on larger strategic transactions.
Key Terms
form 10-k regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
LANGHORNE, Pa., March 31, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the rescheduling of its fourth quarter and fiscal year 2025 financial results conference call to April 8, 2026 at 4:30 P.M. ET to provide additional time for the Company to provide shareholders with greater detail regarding its previously announced proposed transaction with Celularity Inc.
The Company will file its Annual Report on Form 10-K for the year ended December 31, 2025, with the U.S. Securities and Exchange Commission today, March 31, 2026.
Fourth Quarter and Full Year 2025 Financial Results Conference Call Details:
Date: April 8, 2026
Time: 4:30 P.M. ET
Live Call: 1-800-267-6316 (U.S. Toll Free) or 1-203-518-9783 (International)
Webcast: Events and Presentations
About NEXGEL, Inc.
NEXGEL is a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL brands include SilverSeal®, Hexagels®, Turfguard®, Kenkoderm® and Silly George®. Additionally, NEXGEL has strategic contract manufacturing relationships with leading consumer healthcare companies.
Forward-Looking Statement
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “potential,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “lends,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts, including, without limitation, our ability to consummate the potential acquisition and the related additional investment. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see the Company's Annual Report on Form 10-K for the year ended December 31, 2024, including but not limited to the discussion under “Risk Factors” therein, which the Company filed with the SEC and which may be viewed at http://www.sec.gov/.
Investor Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
Nexgel@KCSA.com
